Abliva AB

Rwanda
Byumba, Northern Province, Rwanda, 223 81

Company profile

Abliva AB company profile

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2000-01-01, Year

Headquarters

Postal code
223 81
Country code
RW
Continent
Africa

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
7
Total equity funding
$36.2M
Last funding
Post IPO Equity / $20.5M / 2022-05-31
Last equity funding
Post IPO Equity / $20.5M
Investors
6
Lead investors
5
Founders
1
Articles
48
Exited on
2020-05-29

Founders and investors

Founders

Eskil Elmér

Lead investors

Congressionally Directed Medical Research ProgramsHadean VenturesNyenburgh Investment PartnersU.S. Department of DefenseVinnova

Investors

Congressionally Directed Medical Research ProgramsHadean VenturesIP GroupU.S. Department of DefenseVinnova